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Abstract Objectives:To assess the utility of capsaicin test in the differential diagnosis of non-productive causes of
chronic cough and to examine the effects of treatmenton this reflex.Participants: 86 healthy volunteers and101patients
with chronic cough: asthma (n: 54), gastroesophagealreflux (n: 35) andpost-nasal drip syndrome (n:12).Design: Prospec-
tive intervention trial. Spirometry, bronchoprovocation test with histamine (PC20), and cough challengewith ascending
concentrations of capsaicin (0.49^500 mM) were initially performed in all subjects. Patients were treated for 3 months
according tothe origin ofthe cough.Concentrations thatelicited two (C2) and five ormore coughs (C5) were determined
before and after treatment. Results: In healthy subjects, cough sensitivity to capsaicin was not influenced by gender or
smoking status; however, womenwith chronic coughweremore sensitive to cough challenge thanmen.C2 and C5were
significantly lower in patients with asthma or gastroesophageal reflux than in post-nasal drip syndrome.No significant
correlation was observed between the capsaicin cough threshold and PC20.Cough sensitivity did not improve signifi-
cantly in most patients with asthma or gastroesophageal reflux despite adequate medical treatment during 3 months.
Discriminative value of capsaicintestto differentiate healthy subjects frompatientswith asthma orrefluxwaspoor. Con-
clusions:Cough sensitivity to inhaled capsaicin is a safe and reproducible tool in the study of chronic cough.However, its
usefulness for themanagement and differential diagnosis is limited. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1460, available online athttp://www.sciencedirect.com
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Cough is a common symptom in respiratory disease.
It has been estimated that 10^40% of o⁄ce visits
per year in general practice are due to this symptom(1).
Asthma, gastroesophageal re£ux, and post-nasal
drip syndrome, alone or in combination, account
for the majority of cases of persistent cough in
patients who are referred to pulmonary specialists
(2,3). In these cases, cough usually results from
the stimulation of sensory nerves in the airway
with activation of irritant receptors (myelinated
rapidly adapting stretch receptors) or C-¢ber endings
in the larynx or tracheobronchial tree (4). It has
been suggested that chronic airway irritation, irrespec-
tive of the original cause (in£ammation or aspiration),
may lead to the development of a sensory hyperrespon-
siveness of cough receptors (5,6). According to this hy-
pothesis, the mechanism by which gastroesophagealReceived 28 May 2002, accepted in revised form19 September 2002.
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3868789; E-mail: alfr591@separ.esre£ux, asthma or post-nasal drip syndrome induces
cough may be similar: enhanced sensitization of airway
sensory nerves.
Capsaicin, the active ingredient of red pepper, is a
commonlyused cough stimulant in the studyof cough re-
activity and for the evaluation of antitussive agents in hu-
mans (7^9). It has been shown to produce cough mainly
by stimulating C-¢ber endings and also by stimulating
some rapidly adapting receptors with myelinated ¢bers
(10). Although di¡erent studies(11^13)have demonstrated
that capsaicin is safe to use and produces a dose-depen-
dent and reproducible cough response in a variety of
conditions, there are scarce studies reporting reference
values of cough threshold to inhaled capsaicin in healthy
subjects. Moreover, usefulness of capsaicin challenge in
the diagnostic algorithm of chronic cough has not been
determined (14).
The present study was designed with the following
purposes: (1) to determine our normal range of cough
threshold to inhaled capsaicin, (2) to assess the sensitiv-
ity of capsaicin test in the di¡erential diagnosis of non-
productive persistent cough, and (3) to examine the ef-
fects of treatment of the underlying condition on cough
sensitivity.
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Study subjects
Patients referred to our Service of Pneumology for study
and treatment of unexplained cough of more than 4
weeks durationwere includedin the study.None of them
hadbeenpreviously diagnosed of any chronic respiratory
disease or were taking bronchodilators and/or inhaled
corticosteroids. Additional exclusion criteria were the
presence of acute respiratory infections during the pre-
vious 4 weeks. Active smokers (patients who smoked in
the last month) and patients receiving angiotensin-con-
verting enzyme inhibitors or drugs that may in£uence
airway reactivity or lower esophageal sphincter tone
were also excluded. In order to obtain ourownreference
values, a group of healthy individuals free from respira-
tory disease (normal physical examination and lung func-
tion) participated in the study. The study was approved
by the institutional review board, and written informed
consentwas obtained fromall subjects after thepurpose
of the diagnostic evaluation and the capsaicin challenge
test had been explained.
Study design
Patients with chronic cough underwent a thorough diag-
nostic evaluation (14) that consisted of medical history
(cough characteristics, respiratory, and digestive symp-
toms), physical examination, chest radiography, and pul-
monary function testing including spirometry and
bronchodilator test (Fig.1).When a diagnosis was initially
suspected, a speci¢c diagnostic test was indicated (¢rst
step in the algorithm). In this sense, sinus X-ray ¢lms, his-
tamine challenge, or 24-h esophageal monitoring wereAsthma
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FIG. 1. Diagnostic algorithm for chronic cough. Speci¢c diagnostic
monitoring)wereperformedonanindividualclinicalbasis (¢rst step)
treatment response to adequate 3-month therapy (¢nal step of the
cause, abronchoprovocationhistamine challengewas ¢rstordered.
ful treatment at1monthwas followedbyadditional tests inthe ordeperformed on an individual basis. If the diagnosis
was established by the tests, speci¢c treatment was in-
stituted. One or more ¢nal diagnosis were only estab-
lished after successful treatment response to adequate
3-month therapy.(Final step of the algorithm).When in-
itial clinical ¢ndings did not suggest a speci¢c cause, a
bronchoprovocation histamine challenge was ¢rst or-
dered. If it was negative, a 24-h pH-monitoring was
indicated. Unsuccessful treatment at 1 month was fol-
lowed by additional tests in the order which is indicated
in the algorithm and treatment responsewas newly ree-
valuated.
Asthmawas diagnosed in thepresence of symptoms of
episodic wheezing, cough, and shortness of breath with
positive challenge tests (PC20 histamineo8mg/dl) or in-
creased forced expiratory volume in 1s (FEV1) after
bronchodilator inhalation (([postFEV1preFEV1]/pre-
dicted FEV1)412% and 200ml). Treatment included in-
haled steroids (£uticasone 500mg/day) and salbutamol
as needed. Gastroesophageal re£ux was diagnosed
when the percentage of time with a pH below 4 was
48% for the upright, 44% for recumbent, and 45%
for the total time. Patients with gastroesophageal re£ux
were treated with lifestyle changes and omeprazole
(40mg/day).
Post-nasal drip syndrome was suspected when pa-
tients complained of having something dripping into the
throat, nasal discharge, mucus drainage in the posterior
oropharynx or hoarseness. Laryngitis was diagnosed by
indirect laryngoscopy taking into consideration the pre-
sence of mucosal integrity and erythema. Patients
with post-nasal drip syndrome were treated with
nasal steroids (£uticasone 250mg/day) antihistamines
(loratadine 10mg/day), and topical decongestants (d-iso-
ephredine).Gastroesophageal reflux
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tests (sinus X-ray ¢lms, histamine challenge, or 24-h esophageal
.Oneormore ¢naldiagnosiswereonlyestablishedafter successful
algorithm).When initial clinical ¢ndings did not suggest a speci¢c
If itwasnegative, a 24-hpH-monitoringwasindicated.Unsuccess-
r which is indicated and treatmentresponsewas reevaluated.
COUGHREFLEXTESTING 395Histamine challenge test was performed according to
themethod described by Cockcroft et al. (15).Histamine
doses were inhaled from a Hudson Up Draft II nebulizer
(output 0.137 0.002ml/min) operated by an electric
compressor (Pari TherapiegerNt Privat). FEV1before and
after each inhalation was measured on a dry wedge spi-
rometer (Vitalograph, Vitalograph Ltd., U.K.) and bron-
chial hyperresponsiveness was expressed as the
histamine provocation concentration producing a 20%
fall in the FEV1 (PC20 FEV1).
Gastroesophageal re£ux was measured by 24-h eso-
phageal and gastric pH monitoring using antimony pH
electrodes (Monocrystant 91-0011, Synectics Medical,
Stockholm, Sweden) connected with a dual-channel pH-
meter (Digitrapper Mark III, Synectics). Probes were in-
troduced transnasally and the distal electrode were lo-
cated 5 cm above the upper limit of manometrically
de¢ned lower esophageal sphincter. The proximal elec-
trode was placed immediately under the upper esopha-
geal sphincter. Recorded data were evaluated with an
ambulatory pH software package (Gastrosoft,WI,
U.S.A.). Patients were instructed to lead their normal
lives. Esophagoscopy was also performed in patients
with gastroesophageal re£ux or severe digestive symp-
toms to exclude the presence of esophagitis.
Following the diagnostic protocol and before speci¢c
treatmentwas indicated, patients andhealthy individuals
underwent the capsaicin challenge. Maximum FEV1 and
FVC, ( Vitalograph LTD, Buckingham,U.K.) were deter-
minedbefore and after the capsaicin challenge to investi-
gate the bronchoconstrictor e¡ect of capsaicin. Cough
intensity was measured using a visual decimal scale (0^
10, where 0: no cough and 10: maximal cough) initially
and after treatment.
In order to evaluate the e¡ects of treatment, capsai-
cin cough challenge was repeated after a 3-month treat-
ment period. Likewise, reproducibility of the test was
assessed in healthy subjects at 3 months.
Capsaicin Challenge
Capsaicin (Sigma Chemical, Poole,U.K.) was preparedby
dissolving 30.5mgof the substance in1ml of 96% ethanol
and 1ml of polyoxyethylenesorbitan monooleate 80
(Tween 80) and then dissolved in 8ml physiologic saline
solution tomake a stock solution of102 M.This solution
was further diluted with saline solution to make serial
doubling concentrations ranging from 0.49 to 500mM.
Fresh dilutions were prepared each day of testing. Aero-
sol was delivered through a breath-activated nebulizer
controlled by a dosimeter (Optineb Air Liquid), set to
nebulize for 0.9 s. The challenge was performed by sin-
gle-breath inhalation of doses increasing from 0.49 to
500mM. Subjects were asked to inhale once deeply over
2 s at 2-min intervals. The number of coughs during the¢rst 30 s after each dosewas counted.The challengewas
terminated when the subject cough ¢ve or more times
(C5) or the maximal dose of capsaicin was attained. In
subjects who did not have cough, a value of C5 of
500mMwas assumed.The concentration of capsaicin in-
ducing two coughs (C2) was also recorded. Subjectswere
unaware that cough was the speci¢c point of research
interest.
Statistical analysis
Capsaicin log C2 and log C5 values were expressed as
geometric means and 95% con¢dence intervals (CIs). To
test reproducibility, an intraclass correlation coe⁄cient
was calculated. In assessing the relationship of cough
threshold to age, gender, histamine PC20, FEV1, and dura-
tion of cough, a Pearson’s product^moment correlation
analysis was performed. Di¡erences in clinical variables
in each group were assessed using the Chi-squared test.
In patients with gastroesophageal re£ux, the association
between cough threshold and re£ux severity or the pre-
sence of esophagitis and laryngitis was also investigated.
The di¡erences in mean values for log C2 and log C5 for
the patient groups were evaluated by analysis of var-
iance. A value of Po0.05 was considered to be signi¢-
cant. Changes in capsaicin concentrations after
treatment were expressed in doubling concentrations
[(log capsaicin after treatment  log capsaicin before
treatment)/log 2) and patients divided into responders
(doubling concentrations 41.2 or the cuto¡ point for
the 95th percentile in healthy subjects) and non-respon-
ders. Di¡erences between responders and non-respon-
ders were evaluated by t test for independent samples.
Finally, the ability of the capsaicin challenge test in the
diagnosis of chronic cough was assessed by calculating
the sensitivity, speci¢city, false-positive rate, and false-
negative rate for each inhaled concentration value. The
best cut-o¡ point that separates healthy and the di¡er-
ent groups was obtained with a graphical ROC curve,
constructed by plotting sensitivity against false-positive
rate for each value. Area under curve of the di¡erent
ROC curves were compared. Other cuto¡ values were
obtained corresponding to the values with greatest spe-
ci¢city.
RESULTS
A total of113 patients (41men and 72 women) were initi-
ally studied. In 12 of the 113 cases, a de¢nitive diagnosis
was not established and they were excluded from the
analysis. Baseline characteristics of patients in the study
are shown in Table 1. The underlying causes of chronic
cough included asthma in 54 patients, gastroesophageal
re£ux in 35 (in association with bronchial hyperrespon-
TABLE 1. Baseline characteristics in101patientswith chronic cough
Data Asthma GER GER and BHR PND P value
Age, (years) 41 (17) 47 (14) 52 (15) 38 (18)
Gender, (male/female) 19/35 3/20 3/9 8/4 NS
Cough duration, (months) 30 (38) 49 (44) 30 (28) 24 (20) NS
Cough characteristics, (%)
Productive 20 7 25 18 NS
Paroxysmal 57 41 35 46 NS
Irritative 19 20 40 20 NS
Shortness of Breath, (%) 52 24 57 37 NS
Wheezing, (%) 61* 27 21 33 o0.05 vs.GER and PND groups
Rhinitis, (%) 21 14 20 55* o0.05 vs. Asthma and GER group
Pirosis/Disphagia, (%) 27 78* 48 29 o0.05 vs. Asthma and PND groups
Laryngitis, (%) 7 21 38 10 NS
Esophagitis, (%) NA 36 37 NA NS
GER: gastroesophageal re£ux;BHR: bronchial hyperresponsiveness; PND: post-nasal drip;NA: not applicable.NS: not sig-
ni¢cant.
*Po0.05
Data expressed asmean (SD) or percentage of patients.
396 RESPIRATORYMEDICINEsiveness in12), and post-nasal drip syndrome in12. Inter-
group di¡erences in relation to demographic,
clinical characteristics, and duration of cough were not
signi¢cant. As expected, the frequency of digestive
symptoms and shortness of breath was signi¢cantly
di¡erent in patients with gastroesophageal re£ux or
asthma group.
Eighty-six healthy volunteers (36 men and 50 women)
participated in the study to obtain the reference values.
Results of spirometry and capsaicin challenge of this
group are shown inTable 2.Therewereno di¡erencesbe-
tween capsaicin cough thresholds between smokers and
non-smokers. Likewise they were not in£uenced by gen-
der. However, cough sensitivity was related with age
(r=0.27, Po0.05).
Reproducibility of the capsaicin challenge performed
in this group was high (intraclass correlation coe⁄cient:
0.75 (95% CI 0.53^0.87) and 0.88 (95% CI 0.76^0.94) for
C2 and C5 values, respectively].
There were not any changes in spirometric values fol-
lowing capsaicin challenge.
Results of capsaicin cough challenge in subjects with
chronic cough (Table 2) revealed that patients with asth-
ma or gastroesophageal re£ux showed signi¢cantly low-
er pre-treatment cough threshold concentrations than
healthy subjects or patients with post-nasal drip syn-
drome. In patients with chronic cough, cough threshold
was signi¢cantly lower in women than in men and there
was a statistically signi¢cant inverse relationship be-
tweencough sensitivity and age (r=0.33,Po0.05). Cap-
saicin cough sensitivity was signi¢cantly related to
previous duration of cough, especially in asthmatic pa-
tients (r=0.43, Po0.01). As a whole, no relationship
was foundbetween histamine PC20 and cough sensitivityin patients with chronic cough. This absence of correla-
tionwas also con¢rmed in the asthmatic group.
In patients with gastroesophageal re£ux, log C2 and
log C5 values were not in£uenced by the presence of lar-
yngitis or esophagitis. Capsaicin sensitivity was also not
signi¢cantly di¡erent between patients with proximal or
distal re£ux.
In all patients, cough decreased progressively and al-
most disappeared after 90 days of treatment. However,
in themajority of patientswith asthma or gastroesopha-
geal re£ux, cough re£ex sensitivity did not vary after 3
months of treatment as shown in Fig. 2.There were no
di¡erences in demographic and clinical characteristics,
duration of cough, and bronchial hyperresponsiveness
between responders (n=31) and non-responders
(n=70).
As indicated by the ROC curves (Fig. 3) the optimal
cuto¡ point to di¡erentiate asthmapatients fromhealthy
subjects was 31mM (sensitivity 94%, speci¢city 50%) and
the optimal cuto¡ point to distinguish patients with gas-
troesophageal re£ux from healthy subjects was 15mM
(sensitivity 98%, speci¢city 66%). The area under the
ROC curve was slightly higher in patients with gastroe-
sophageal re£ux (0.88, SD=0.41) than in patients with
asthma (0.82, SD=0.36). The lowest cuto¡ point in
healthy subjects was 125mM.Capsaicin threshold higher
than this value showed a 100% speci¢city for excluding
sensory hyperresponsiveness as the cause of cough.
DISCUSSION
We have demonstrated that testing cough sensitivity to
inhaled capsaicin is a safe and reproducible tool in the
TABLE 2 Results of capsaicin cough challenge in 86 healthy subjects and in101patientswith chronic cough
Patientswith chronic cough
Data Healthy subjects Total Asthma GER GER and BHR PND P-value
FEV1 (l/min)
Baseline 3.40 (0.78) 2.57(0.73) 2.56 (0.82) 2.59 (0.75) 2.50 (0.78) 2.58 (0.75) NS
Post-capsaicin 3.59 (0.92) 2.58(0.71) 2.55 (0.81) 2.59 (0.69) 2.48 (0.79) 2.58 (0.76) NS
FVC (l/min)
Baseline 4.22 (0.87) 3.30(0.85) 3.38 (0.91) 3.39 (0.85) 3.14 (0.96) 3.49 (0.69) NS
Post-capsaicin 4.54 (1.05) 3.33(0.79) 3.42 (0.94) 3.31 (0.81) 3.18 (1.06) 3.43 (0.92) NS
Histamine PC20, (mg/ml) 8.48(5.8) 3.63 (2.02) * 11.9 (2.23) 3.68 (2.42)* 11.1 (3.01) o0.05 vs.GER and
PND groups
C2 before treatment (mM) 32.3 (23.4^44.6) 13.8 (6.3^29.5)* 4.8 (2.2^10.7) * 5.4 (2.4^12.6) * 77.6 (32.3^186) o0.05 vs. healthy and
PND groups
Men 33 (21to 56) 24 (15^41)
Women 32 (21to 49) 7 (5^10) * o0.05 vs.male gender
Smokers 33 (22 to 45)
Non-smokers 31 (20 to 57)
C5 before treatment (mM) 151 (123 to186) 33.3 (22.1^48) * 14.3 (6.3^29.5) * 12.3 (4.6^32.3)* 117 (57^239) o0.05 vs. healthy and
PND groups
Men 141 (104 to190) 55 (34^87)
Women 158 (120 to 209) 29 (13^30) * o0.05 vs.male gender
Smokers 131 (105 to189)
Non-smokers 144 (103 to192)
D C2, (doublingdoses) 0.14 (1.6) 0.62 (1.9) 0.81 (1.92) 0.29 (2.4) 0.01 (0.01) 0.57 (1.27) NS
D C5, (doublingdoses) 0.01 (0.75) 0.67 (2.1) 0.63 (1.5) 0.52 (2.16) 0.13 (2.4) 1.29 (2.29) NS
*GER: gastroesophagealre£ux;BHR: bronchialhyperresponsiveness;PND: post-nasal drip;NS: notsigni¢cant.
Po0.05.
Data expressed asmean (SD) or geometricmean (95% CI).
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FIG. 2. Individual values of capsaicin concentration before and after 3 months of treatmentof the underlyingdisease in patientswith
chronic cough and inuntreatedhealthy subjects.
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FIG. 3. ROC curves of optimal capsaicin cut-o¡ points to dis-
tinguish patients with asthma (K) or gastroesophageal re£ux
(~) fromhealthy subjects.
398 RESPIRATORYMEDICINEstudy of non-productive chronic cough. However, its
usefulness for themanagement and di¡erential diagnosis
is limited.
Sensory hyperresponsiveness to capsaicin was only
seen in patients with asthma or gastroesophageal re£ux.
Patients with post-nasal drip syndrome were found to
havenormal sensitivityof the coughre£ex and, therefore,
were di¡erent from the remaining patients with chronic
cough.The absence of this response is important because
it could serve to exclude this condition in clinical practice.
Cough sensitivity, whichwas independentof bronchial hy-
perresponsiveness even in asthmatic patients, was only
related to the duration of the symptom and gender. A
heightened sensitivity of the cough re£ex to inhaled cap-
saicin inwomen comparedwithmenwas found.
Reference values in healthy subjects have not been
clearly established due to the lack of standardization of
assessment of cough sensitivity to inhaled capsaicin and
the relatively small number of healthy subjects included
in the di¡erent studies.C2 andC5were arbitrarily chosen
COUGHREFLEXTESTING 399for comparison with international literature. Our mean
C2 and C5 values of 32 (23^44) and151 (125^186) mM, re-
spectively, in normals are similar than ¢ndings reported
by Choudry and Fuller (12). In contrast to sex di¡erences
reported by Fujimura et al. (16) and by Dicpinigaitis and
Rauf (17), cough threshold in our series was similar in
males than in females. In the former studies, gender dif-
ferencewas a signi¢cant predictive factor for cough sen-
sitivity in either agegroup.Likewise, gender in£uencehas
been documented in other modalities of evoked cough
(citric acid, tartaric acid). Reproducibility of the test in
28 healthy subjects who took part in both the ¢rst and
second experiments (3 months apart) was good, with a
high intraclass correlation coe⁄cient, i.e., equal to or
less than 1 as expressed in doubling concentrations. Re-
producible cough responses to capsaicin challenge in
both adults and children have been previously found by
others (11,16,18).
Little has been reported on theusefulness of capsaicin
test in studies of the cough re£ex in disease. Choudry
and Fuller12 found that patients with non-productive
cough had a higher sensitivity of the cough re£ex (log
C5:1.16) than patients with productive cough (log C5:1.54)
or healthy subjects (logC5:1.78). Increasedcough sensitiv-
ity was also found in patients given angiotensin-convert-
ing enzyme inhibitors, in patients with previous viral
infections, and in patients with gastroesophageal re£ux.
In the latter, tussive response to capsaicinwas enhanced
even in patientswithout cough (13,19).The reason for this
response is not clear. Any parameter of esophageal func-
tion or re£ux is associated with the reduced cough
threshold. It has been hypothesized that long-lasting ex-
posure of themucosa to gastric juices could produce en-
hancement of the cough re£ex.
Airway in£ammation in patients with asthma is prob-
ably the cause of the increased sensitivity to capsaicin.
However, mechanisms underlying cough production are
not always related to those determining bronchial reac-
tivity. In the present study, sensory hyperresponsiveness
to capsaicin in patients with asthma was independent of
bronchial hyperresponsiveness to histamine.
In healthy individuals, several studies have not found
di¡erences between smokers and non-smokers (12).
These ¢ndings are in agreementwith thepresentresults.
Cough is a frequent symptom in smokers and patients
with COPD. Previous studies showed that patients with
chronic bronchitis had normal responses to capsaicin
(20); however, Doherty et al. (21) have demonstrated
thatcoughre£ex is also increased inpatientswith COPD
and it is independentof air£ow limitation.Upper respira-
tory infection may cause cough as a result of increased
sensitivity of capsaicin-sensitivity a¡erent airway nerves
without a¡ecting airway calibre or responsiveness.
O’Connell et al. (22) have shown that in subjects with
dry cough C5 was lower during infection than both base-
line and recovery.No previous data have been reported in relation to
the diagnostic accuracy of capsaicin cough challenge in
terms of sensitivity and speci¢city.With a cuto¡ point of
15mM, the predictive capacity of the test for di¡erentiat-
ing patients with chronic cough from those with gastro-
esophageal re£ux was higher than for di¡erentiating
patients with chronic cough from asthmatics or patients
with post-nasal drip syndrome. In case of using results of
capsaicin challenge in diagnostic algorithms, they would
seemparticularly useful to exclude the diagnosis of post-
nasal drip syndrome in a patient with chronic cough.
On the other hand, studies of capsaicin sensitivity
after successful treatment of cough are limited. In pa-
tients with gastroesophageal re£ux, some authors (19)
have shown that omeprazol improves not only digestive
symptomsbut also the cough threshold to capsaicin.This
improvement was signi¢cant after 5 days in most of the
patients. In the present study, cough sensitivity remains
increased despite favorable clinical response to treat-
ment both in asthma and gastroesophageal re£ux. The
inclusion of patients without cough in the former study
could explain some of the di¡erences. Likewise, several
studies have documented that multiple causes may be
present in the individual patient.This feature couldmod-
ify theresults of the capsaicin test.To avoid it,we choose
only patients who responded successfully to speci¢c
treatment.Weprefer this stepping approach instead that
everypatienthashad all examinations.Thepersistence of
cough re£ex sensitivity may add a valuable objective
parameter to continue with treatment until a normal
sensitivity has been attained.
In summary, capsaicin challenge has a limited useful-
ness in the di¡erential diagnosis andmanagement of dis-
eases causing an increase in the sensitivity of cough
re£ex.
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